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PMH5
THE EFFECT OF RIVASTIGMINE ON THE 
DIRECT AND INDIRECT COSTS OF 
ALZHEIMER’S DISEASE
Brooks E, Deal L
Research Triangle Institute, Center for Economics Research, 
Research Triangle Park, NC, USA
A recent study used data from two Phase III clinical trials of
rivastigmine efficacy and safety to model rivastigmine’s ef-
fect on the progression of Alzheimer’s disease (AD). In these
trials, a patient’s AD status is gauged by measuring cog-
nitive function using the mini-mental state exam (MMSE).
The hazard model developed in this study has been used
to estimate disease stage-specific savings in direct cost of
caring for AD patients resulting from treatment with ri-
vastigmine. OBJECTIVES: We refined this model to esti-
mate precise MMSE score-specific savings and investigate
the distribution of cost savings across direct and indirect
costs of caring for AD patients. METHODS: MMSE score-
specific estimates of AD progression in both untreated and
treated patients were combined with both MMSE score-
specific estimates of direct and indirect costs of AD, and
estimates of the probability of institutionalization from
previous studies. We estimated potential savings due to
rivastigmine treatment in direct, indirect, and total costs
of caring for AD patients in the US. We analyzed the rel-
ative magnitudes of these cost savings across MMSE
scores for three treatment time horizons. RESULTS: As a
percentage of total gross cost savings, savings in indirect
costs are greatest for both mild and moderate patients
during the first 6 months of treatment. After 2 years of
treatment, gross direct cost savings make up the majority
of overall cost savings for both mild and moderate pa-
tients. CONCLUSIONS: Decreases in likelihood of insti-
tutionalization resulting from treatment appear to be
driving these results. Results clearly demonstrate long-
term savings of early initiation of rivastigmine treatment.
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PHARMACOECONOMIC ANALYSES OF DEPOT 
NEUROLEPTIC TREATMENT IN 
NATURAL SETTING
Gurovich I1, Kobina S2, Lyubov E1, Litvischenko Y2, 
Shmukler A1
1Moscow Research Institute of Psychiatry of the Russian 
Federation, Moscow, Russia; 2Aventis Pharmaceuticals, Inc., 
Moscow, Russia
OBJECTIVES: The study purpose was to evaluate cost-
effectiveness for the treatment with some depot neurolep-
tics (decanoate zuclopenthixol, decanoate flupenthixol,
palmitate pipothiasine) for patients with schizophrenia
(ICD-10) in a Moscow community psychiatric outpatient
clinic compared with oral forms of conventional neuro-
leptics. METHODS: In the frame of the first (clinical)
stage a 24-week mirror-image cost-effectiveness study
was performed. Three cohorts of 34, 29 and 29 patients
at high risk of relapse or frequent exacerbation of schizo-
phrenic symptoms and consequent hospitalization were
treated with decanoate zuclopenthixol, decanoate flu-
penthixol, palmitate pipothiasine, respectively. Clinical
improvement was evaluated with PANSS  CGI, and dy-
namic of social functioning and quality of life of patients
with original checklist. Severity of extrapyramidal side
effects was evaluated with Simpson-Angus scale. Cost
analysis was performed including relevant data about the
direct and indirect costs (rub. 1998) for all of the pa-
tients. At the second (analytic) study stage by means of
decision tree simulation model an economic evaluation of
treatment with the depot neuroleptics over a hypothetical
five-year period was performed. RESULTS: Statistically
significant clinical improvement along with improvement
of social functioning and quality of life of all of the pa-
tients receiving depot were achieved. Economic analysis
indicated significant (50%) saving in the total medical
cost associated with the patients despite the fact that
these medicines have a higher acquisition cost. Twice as
much gain was achieved from the societal perspective.
Analytic method confirms that long-term treatment with
the depot antipsychotics is cost-effective versus standard
oral ones. CONCLUSIONS: The treatment of schizo-
phrenia with studied Depot neuroleptics should be con-
sidered as an evidence based (first line) maintenance
strategy in usual practice setting especially for outpa-
tients with problems of compliance.
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COST-EFFECTIVENESS OF ATYPICAL 
ANTIPSYCHOTICS IN CHRONIC 
SCHIZOPHRENIA
Karki SD1, Bellnier TJ1, Hager EP2
1SUNY, School of Pharmacy, Buffalo, NY, USA; 2Rochester 
Community Individual Practice Association, Rochester, NY, 
USA
Atypical antipsychotics have equal or better clinical effi-
cacy and more favorable side effect profiles when com-
pared with typical antipsychotics and are increasingly
prescribed. Cost-effectiveness approach will guide the in-
stitutions to optimize the limited medication budget. OB-
JECTIVE: The purpose of this study is to compare the
cost-effectiveness of three atypical antipsychotics; cloza-
pine, risperidone and olanzapine. METHODS: Patients,
treatment refractory to conventional antipsychotics, were
started on clozapine or risperidone or olanzapine in an
open-label, prospective effectiveness and safety evalua-
tion. Subjects from each treatment group were matched
for age, sex, ethnicity, diagnosis, current length of hospi-
talization and baseline BPRS scores. Samples of 50 pa-
tients were randomly selected from each effectiveness and
safety evaluation to compare cost-effectiveness by using
the change in BPRS score after six months of treatment.
RESULTS: BPRS scores were 61, 59, and 59 at baseline
and 42, 54 and 42 for clozapine, risperidone and olanza-
pine at the end of six months. Average prescriptions costs
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were $17.44, $9.21 and $13.96 ans the cost/(change in
BPRS) were $2.91, $4.13 and $2.41 for clozapine, ris-
peridone and olanzapine respectively indicating olanza-
pine as the most cost-effective. The difference between
the cost/(change in BPRS) for olanzapine and risperidone
was statistically significant (P  0.036, t  2.1234,
df  98) ($1.72[$3.54–$0.10]). CONCLUSION: Re-
sults of our evaluation indicate that olanzapine is the
most cost-effective antipsychotic in our population of se-
vere and persistently mentally ill patients with schizo-
phrenia and schizoaffective disorders. We recommend
that simple cost-effective evaluations be made in every in-
stitution before deciding on the formulary or the pre-
ferred status of any atypical antipsychotic as it depends
upon many variables.
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COST-EFFECTIVENESS OF STRATIFIED CARE IN 
THE MANAGEMENT OF MIGRAINE
Rapoport A1, Lipton RB2, Williams P3, Sawyer J4
1New England Center for Headache, Stamford, CT, USA; 
2Albert Einstein College of Medicine and Innovative Medical 
Research, New York, NY, USA; 3Genesis Pharma Strategies, 
Beaconsfield, UK; 4AstraZeneca, Macclesfield, UK
The Disability In Strategies for Care (DISC) study dem-
onstrated that stratified care (where more disabled pa-
tients commenced treatment with zolmitriptan 2.5mg) re-
sulted in superior clinical outcomes compared with
conventional stepped care (where patients commenced
the same treatment regardless of disability). However
there are no prospective studies of the cost-effectiveness
of stratified care. OBJECTIVE: To assess the cost-effec-
tiveness of stratified care in managing migraine. METH-
ODS: A decision-analytic model was built to represent
primary care treatment of migraineurs under stepped and
stratified care, according to the treatment regimens in the
DISC study. A health service perspective was adopted,
with a one year time horizon. Data inputs were (i) the
frequency and disability of migraine, derived from popu-
lation-based studies. (ii) disability level-specific treatment
response rates for OTC analgesics, aspirin/metoclopra-
mide and zolmitriptan were obtained from an interna-
tional Delphi study; (iii) unit costs of healthcare in the US
(drug costs, primary and secondary care consultation
costs) obtained from health service sources. RESULTS:
The model estimated the cost per successfully treated at-
tack as $80 for stepped care and $45 for stratified care.
The estimated one-year direct healthcare costs were $534
for stepped care and $546 for stratified care. Estimates of
treatment response rates were 40% and 71% for stepped
and stratified care respectively.The incremental cost-
effectiveness for stratified care was $2.12 per additional
successfully treated attack. The cost-effectiveness of strat-
ified care was robust when tested in a wide range of sen-
sitivity analyses. CONCLUSION: Stratified care is a highly
cost-effective method of managing migraine delivering
improved clinical outcomes at minimal additional cost.
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A MANAGED CARE VALIDATION PROGRAM 
FOR A PHARMACOECONOMIC MODEL OF 
MAJOR DEPRESSION
Casciano J1, Arikian S1,2, Doyle JJ1,2, Casciano R1
1The Analytica Group Ltd., New York, NY, USA; 2Columbia 
University, School of Public Health, New York, NY, USA
Managed care companies vary substantially in the health-
care management of their membership as well as the fi-
nancial and contractual arrangement with their provider
networks. Therefore, formulary decision-makers could
benefit from customization of pharmacoeconomic deci-
sion models with plan-specific information. OBJEC-
TIVE: The purpose of this analysis was to validate results
of a pharmacoeconomic model for major depression by
customizing clinical and financial datasets specific to five
managed care organizations (MCOs). METHODS: A
pharmacoeconomic model was developed using decision
tree analysis over a six-month time horizon to assess the
acute phase of major depression for inpatients and out-
patients. Success and failure rates for TCAs, SSRIs and
SNRIs were obtained from a recent meta-analysis. Health-
care resources were incorporated into the model to deter-
mine the inpatient and outpatient costs of patient out-
comes. To facilitate site-specific customization of the
model, a software tool was developed enabling revisions
to the base-case practice patterns, resource valuation and
epidemiologic data. The model calculated expected cost
per patient, expected cost per-member-per-month (PMPM),
total annual cost, and 5-year total cost. RESULTS: Over
the five plans, the expected annual cost per outpatient
was the lowest for venlafaxine at $1,364 to $3,177 and
the highest for SSRIs at $1,881 to $4,311. Similarly, the
expected annual cost per inpatient again was the lowest
at $6,477 to $16,305 for venlafaxine and the highest at
$6,963 to $18,171 for the TCAs. CONCLUSIONS: Al-
though results varied across the five customizations of
the model, venlafaxine XR was the lowest cost alterna-
tive for all plans, validating the pharmacoeconomic re-
sults of the original model.
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A MODEL TO PERFORM ECONOMIC 
EVALUATIONS OF INTERVENTIONS FOR 
ACUTE MUSCULAR LOW BACK PAIN
Neighbors D1, Earnshaw SR1, Bell L1, Bhattacharyya SK2
1Research Triangle Institute, Research Triangle Park, NC, USA; 
2Procter and Gamble Pharmaceuticals, Mason, OH, USA
Acute muscular low back pain (LBP) accounts for over
$30 billion in US annual medical costs, and is a leading
cause of absenteeism. LBP represents 16% of workers’
compensation claims and 33% of worker’s compensation
costs. Successful LBP treatment can yield substantial sav-
ings for the healthcare system and employers. OBJEC-
TIVE: To develop a model to estimate changes in health-
care utilization, absenteeism, and cost resulting from LBP
